Description

The EORTC Breast Cancer Group (BCG) is a multidisciplinary group aiming to challenge, re-define and develop standards of care in all controversial areas of Breast Cancer diagnosis and therapy, including rare conditions such as male breast cancer. The group researches long-term outcomes and follows all patients until they die.

Main Achievements

Demonstrated breast-conserving therapy has similar efficacy compared to mastectomy (EORTC 10801)

Showed that chemotherapy before or after surgery yielded similar results in terms of survival (EORTC 10902)

Demonstrated that axillary radiotherapy after a positive sentinel lymph node provides excellent and comparable regional control when compared to axillary lymph node dissection, with the benefit of decreased morbidity (AMAROS)

Demonstrated that in some early-stage breast cancer, patients traditionally deemed high risk for disease recurrence based on clinical and biological criteria can have chemotherapy safely omitted without a difference in outcome, in case of a low-risk 70-gene signature result (MINDACT) More information

Related Projects

10085 (MALE BC)-related project

  • RP 1539 (RNAseq): Male breast cancer RNA sequencing (Project leader: John Martens)
    Status: Analyses of first 70 patients completed, additional analyses will follow. Plan is to submit an abstract with the first results for SABCS 2017.

10041 (MINDACT)-related projects

  • RP 0906 (Blue Print): comparison of microarray readout with IHC/FISH for to molecular subtyping profile (BluePrint) (Project leaders: Fatima Cardoso, Giuseppe Viale, Femke de Snoo, Leila Russo, Lisette Stork-Sloots)
    Status: Manuscript was submitted
  • RP 1556 (MINDACT multifocal): Characterisation of multifocal disease in the MINDACT study (Project leaders: Emiel Rutger, Anne Kuijer, Marieke Straver).
    status: Manuscript was submitted

10994 (p53)-related projects

  • RP 1644 (p53-LocoReg): Predictive factors of locoregional recurrence after neoadjuvant chemotherapy in locally advanced breast cancer: a retrospective analysis of the EORTC 10994/BIG1-02 study (Project leader: Hervé Bonnefoi)
    Status: Manuscript was submitted

Research Group

Group documents
  • Chair

    Fatima Cardoso

    Champalimaud Cancer Center

    Lisbon, Portugal

  • Secretary

    Etienne Brain

    Institut Curie – Hopital Rene Huguenin

    Paris, France

  • Treasurer

    Emiel Rutgers

    The Netherlands Cancer Institute
    Antoni van Leeuwenhoekziekenhuis

    Amsterdam, Netherlands

Steering Committee

  • M. Arnedos - Villejuif, FR

    /

    Gustave Roussy

  • H. Bonnefoi - Bordeaux, FR

    /

    Institut Bergonie

  • D. Cameron - Edinburgh, GB

    /

    Western General Hospital

  • M. Ignatiadis - Brussels, BE

    /

    Institut Jules Bordet

  • B. Linderholm - Goteborg, SE

    /

    Sahlgrenska Universitetssjukhuet

  • K. Pogoda - Warsaw, PL

    /

    Maria Sklodowska-Curie Memorial Cancer Centre

  • A. Peric - Brussels, BE

    /

    EORTC Headquarters

  • C. Poncet - Brussels, BE

    /

    EORTC Headquarters

  • N. Russell - Amsterdam, NL

    /

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

  • E. Senkus-Konefka - Gdansk, PL

    /

    Medical University Of Gdansk

  • K. Tryfonidis - Brussels, BE

    /

    EORTC Headquarters

  • L. Van'T Veer - San Fransisco, US

    /

    UCSF Helen Diller Family Comprehensive Cancer Center

  • P. Vuylsteke - Namur, BE

    /

    CHU Ucl Namur - Site Sainte-Elisabeth

  • C. Drukker - Amsterdam, NL

    /

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis